Publication
Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.
Orazio Caffo, Teodoro Sava, Umberto Basso, Sebastiano Buti, Giovanni Lo Re, Cosimo Sacco, Michele Lodde, Gaetano Facchini, Fable Zustovich, Alessandra Perin, Lucianna Russo, Antonello Veccia, Enzo Galligioni
Journal of Clinical Oncology, February 2013, American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2013.31.6_suppl.90